Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This research study involves testing the safety and efficacy of an investigational
intervention for patients with triple-negative breast cancer (TNBC) that has spread, or
metastasized, to other parts the body and is PD-L1-negative.
The names of the study interventions involved in this study are:
- Sacituzumab govitecan (Trodelvy™;IMMU-132)
- Pembrolizumab (Keytruda®; MK-3475)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Gilead Sciences Immunomedics, Inc. Merck Sharp & Dohme Corp.